Maven Securities LTD Cellectar Biosciences, Inc. Transaction History

Maven Securities LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$6.1 - $10.2 $3.73 Million - $6.24 Million	-611,300 Reduced 60.45%	400,000 $266,000
Q3 2021 Nov 15, 2021	BUY	$8.2 - $12.4 $2.96 Million - $4.48 Million	361,300 Added 55.58%	1,011,300 $935,000
Q2 2021 Aug 16, 2021	SELL	$11.8 - $18.2 $2.95 Million - $4.55 Million	-250,000 Reduced 27.78%	650,000 $793,000
Q1 2021 May 17, 2021	SELL	$15.2 - $25.0 $12.5 Million - $20.6 Million	-825,000 Reduced 47.83%	900,000 $1.45 Million
Q4 2020 Feb 12, 2021	BUY	$11.2 - $27.7 $19.3 Million - $47.8 Million	1,725,000 New	1,725,000 $3.71 Million

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $1.47M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.